Immune Cell Therapies: Advances in Cancer and Autoimmune Disease (X4)
March 16-19, 2025
| Fairmont Banff Springs, Banff, AB, Canada
Katy Rezvani, Nathan Singh and Stephan Mielke
Scholarship Deadline: Dec. 10, 2024 | Abstract Deadline: Feb. 21, 2025 | Early Registration Deadline: Jan. 29, 2025
| 4:00–8:00 PM |
Registration |
Van Horne Foyer |
| 6:00–8:00 PM |
Welcome Mixer |
Van Horne Foyer |
| 7:00–8:00 AM |
Breakfast |
President's Hall |
| 8:00–9:30 AM |
Welcome and Keynote Session (Joint) |
Van Horne A |
| |
* Anna Christina Obenauf, Research Institute of Molecular Pathology
Session Chair |
|
| |
* Katy Rezvani, University of Texas MD Anderson Cancer Center
Session Chair |
|
| |
Carl H. June, University of Pennsylvania
Cell Therapies: Current State-of the Art |
|
| |
Ton N. Schumacher, Netherlands Cancer Institute
Dissecting T Cell Recognition of Cancer |
|
| 9:30–9:50 AM |
Coffee Break |
Van Horne Foyer |
| 9:50–9:55 AM |
Award Recipient Acknowledgement |
Van Horne A |
| 9:55–12:00 PM |
Overcoming Challenges in Immune and Cell Therapy: Insights into Mechanisms of Failure and Solutions (Joint) |
Van Horne A |
| |
* Nathan Singh, Washington University School of Medicine
Genomic Regulation of CAR-Driven T Cell Dysfunction |
|
| |
* Anna Christina Obenauf, Research Institute of Molecular Pathology
Rational Combination of Therapies to Stimulate the APC Compartment |
|
| |
May Daher, MD Anderson Cancer Center
Metabolic Interventions to Enhance Adoptive Cellular Therapies |
|
| |
Christopher Harvey, Phenomic
AI/ML-Driven Discovery of a Novel Proteoglycan for Precision Targeting of Solid Tumors by T Cell Engagers |
|
| 12:00–1:00 PM |
Poster Setup |
Van Horne C |
| 12:00–2:30 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
Van Horne C |
| 2:30–4:30 PM |
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
Van Horne A |
| |
* Stephan Mielke, Karolinska Institutet
Session Chair |
|
| |
Xinchen Wang, Waypoint Bio
In Vivo Spatial Pooled Screening Identifies CAR T Constructs with Superior Anti-Solid Tumor Efficacy and Safety |
|
| |
Ju-Fang Chang, Washington University in St Louis
Generation of MHC-Independent T Cell Receptors Using Rational Protein Engineering |
|
| |
Reno Debets, Erasmus MC Cancer Institute
Human T Cell Receptors Equipped with Inducible Co-Stimulator Mediate Durable Anti-Tumor Activity |
|
| |
Hector Caballero Gonzalez, Cellply Srl
Single-Cell Profiling Reveals Functional Dynamics Of Adapter CAR-T Cells Targeting CD33+ Acute Myeloid Leukemia |
|
| |
Jemma Larson, University of Minnesota
Striking a Balance: Human CAR19+ CD8-Itreg for Prevention of GVHD And Enhanced Anti-Leukemic Efficacy Without Systemic Toxicity |
|
| |
Yinghui Jane Huang, University of Pennsylvania
Continuous Expression of TOX Safeguards Exhausted CD8 T Cell Epigenetic Fate |
|
| |
Corbett Berry, University of Pennsylvania
Asymmetric Epigenetic and Metabolic Remodeling of Engineered CD4 T Cells Drives Divergent Cell Fate |
|
| |
Grant G Welstead, Century Therapeutics
Generation of iPSC-Derived CD4+ and CD8+ CD19 CAR T Cells with Robust in Vivo Tumor Control and Persistence |
|
| |
Zoila I Fernandez, Stanford University
Myeloid Cell States as Regulators Of CAR-T Cell Function |
|
| 4:30–5:00 PM |
Coffee Available |
Van Horne Foyer |
| 5:00–7:00 PM |
Cell Therapies for Solid Tumors |
Van Horne A |
| |
Nicholas Vitanza, Seattle Children’s / University of Washington
Advancing Locoregional CAR T Cell Therapy for Pediatric CNS Tumors |
|
| |
* Marcela V. Maus, Harvard Medical School
Driving Complex CAR-T into the Clinic – What, Why, and How |
|
| |
Andras Heczey, Baylor College of Medicine
Cytokine Armored GPC3-CAR T Cells for Patients with Solid Tumors |
|
| |
Tori Yamamoto, Gladstone Institutes
Short Talk: In Vivo CRISPRa Screens Uncover Positive and Negative Regulators of T Cell Accumulation in the Immunocompetent Tumor Microenvironment |
|
| |
Filippo Birocchi, MGH
Short Talk: Balancing Efficacy and Safety: Overcoming On-Target Off-Tumor Toxicity of Claudin18.2-Directed CAR-T Cells in Preclinical Models |
|
| 7:00–8:00 PM |
Social Hour with Lite Bites |
President's Hall |
| 7:30–10:00 PM |
Poster Session 1 |
Van Horne C |
| 7:00–8:00 AM |
Breakfast |
President's Hall |
| 8:00–10:00 AM |
Diversity, Access and Pathways to Regulatory Approval |
Van Horne A |
| |
Stephan Mielke, Karolinska Institutet
CAR T Cells: A European Perspective |
|
| |
* Rayne H. Rouce, Baylor College of Medicine
Improving Access to Cell Therapies |
|
| 9:00–9:20 AM |
Coffee Break |
Van Horne Foyer |
| 10:00–1:00 PM |
Poster Setup |
Van Horne C |
| 10:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
Van Horne C |
| 3:00–4:30 PM |
Career Roundtable (Joint) |
Van Horne B |
| |
Wolfgang Karl Kastenmueller, Institute of Systems Immunology, Max-Planck Research Group
Professor and Director |
|
| |
Rayne H. Rouce, Baylor College of Medicine
Associate Professor |
|
| |
Kristian Hedstrom, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Chief Scientific Officer |
|
| |
Frank P Stegmeier, Curie.Bio
CSO Partner |
|
| |
Fabiola V Rivas, Immunity
Deputy Editor |
|
| 4:30–5:00 PM |
Coffee Available |
Van Horne Foyer |
| 5:00–7:00 PM |
Cell Therapy for Autoimmune Diseases |
Van Horne A |
| |
* Andreas Mackensen, University Hospital of Erlangen
CAR T Cells for B-cell mediated Autoimmune Disease |
|
| |
Gwendolyn Binder, Cabaletta Bio
Clinical and Translational Development of Engineered T Cell Therapy for Autoimmune Disease |
|
| |
Megan K. Levings, University of British Columbia
CAR Tregs |
|
| |
Eleanor Chen, The University of British Columbia
Short Talk: Alloantigen-Specific CAR Tregs Mediate Islet Protection By Suppressing Islet Autoantigen-Specific T Cells |
|
| 7:00–8:00 PM |
Social Hour with Lite Bites |
President's Hall |
| 7:30–10:00 PM |
Poster Session 2 |
Van Horne C |
Wednesday, March 19, 2025
| 7:00–8:00 AM |
Breakfast |
President's Hall |
| 8:00–11:00 AM |
Alternative Immune Effectors |
Van Horne A |
| |
* May Daher, MD Anderson Cancer Center
Session Chair |
|
| |
Michael Klichinsky, Carisma Therapeutics
Remote Presentation: CAR-M: Engineering Myeloid Cells ex vivo and in vivo for Cancer Immunotherapy |
|
| |
Katy Rezvani, University of Texas MD Anderson Cancer Center
Engineering NK Cells for Cancer Immunotherapy |
|
| |
Jode Goodridge, Fate Therapeutics
Use of iPSC for Programmed Cellular Immunotherapies |
|
| |
Jurgen Kuball, University Medical Center
Mastering Diversity of gdT Cells and the Receptors for Cancer Immune Therapies |
|
| |
Shelby Namen, Washington University in St. Louis
Short Talk: CAR Engineered Dcs Respond to Tumor in a Signaling Distinct Manner |
|
| |
Yeara Jo, University of California, Berkeley
Short Talk: Elucidating Molecular Mechanisms of NK Cell Function from the Studies of NK Cell Desensitization and Exhaustion for Improved Anti-Cancer Therapies |
|
| 9:00–9:20 AM |
Coffee Break |
Van Horne Foyer |
| 11:00–2:30 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions |
Van Horne A |
| |
* Mark Leick, Massachusetts General Hospital Cancer Center
Session Chair |
|
| |
Maxwell Foisey, University of California San Francisco
Hybrid-R: Overcoming Limitations in T Cell Therapy With A Single Synthetic Receptor |
|
| |
Robert J. Hofmeister, Myeloid Therapeutics
Innate Immune Receptor-Based Cars For In Vivo Programming of Myeloid Cells to Combat Solid Tumors |
|
| |
Alexander Kim, Washington University School of Medicine
Amyloid Plaque Targeting Chimeric Antigen Receptor Macrophages for Alzheimer’s Disease Therapy |
|
| |
Clara Soulard, CHU Sainte Justine
Exploring the Potential Of CAR-Engineered Hscs for Treating B-Cell Acute Lymphoblastic Leukemia |
|
| |
Kevin Salim, BC Children's Hospital Research Institute/University of British Columbia
Differentiation of Human CD4+ T Cells from Pluripotent Stem Cells |
|
| |
Ritu Bohat, MD Anderson Cancer Center
Enhancing CAR-NK Potency and Persistence with Myd88/CD40 Costimulation |
|
| 4:30–5:00 PM |
Coffee Available |
Van Horne Foyer |
| 5:00–6:30 PM |
Engineering in Cancer Immunotherapy to Enhance Efficacy (Joint) |
Van Horne A |
| |
Rosandra Natasha Kaplan, NCI, National Institutes of Health
Remote Presentation: Engineering of Myeloid Cells |
|
| |
Jaehyuk Choi, Northwestern University
Nature Inspired Design |
|
| |
* Julia Carnevale, University of California, San Francisco
CRISPR-Based T Cell Editing to Enhance Cell Therapy |
|
| 6:30–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (Joint) |
Van Horne A |
| 7:00–8:00 PM |
Social Hour with Lite Bites |
President's Hall |
| 8:00–9:00 PM |
Entertainment |
Van Horne B |
